Pembrolizumab Gains Expanded Monotherapy Indication for First-Line Treatment of NSCLC
The FDA has approved Keytruda as monotherapy for the first-line treatment of patients with stage III NSCLC.
Lung Cancer
Complementary, Alternative Medicine Use High in Cancer Patients
One-third of cancer patients and survivors use complementary and alternative medicine.
Caregiving for Older Cancer Patients Takes Emotional Toll
Poorer cancer patient health tied to higher levels of caregiver distress in informal caregivers.
Smoking in Patients With Cancer Increases Costs by $3.4 Billion
Cost estimates are based on additional treatment following higher failure risk for first-line cancer treatment.
Pembrolizumab Beneficial for Advanced Small Cell Lung Cancer
The objective response rate was 19.3% in patients with incurable, advanced small cell lung cancer.
Emotionally Responsive Virtual Coach Helps Address Patient Concerns in New Simulation
Kognito, a health simulation company, is applying its simulation technology to patient education, to address a gap in patient knowledge.
NSCLC Response to Chemotherapy Predicted by Radiomic Features
In patients with lung adenocarcinoma, radiomic texture features extracted from within and around the nodule on baseline computed tomography can predict a response to chemotherapy.
Atezolizumab Plus Chemotherapy Approved for Initial Treatment of Extensive-Stage Small Cell Lung Cancer
The Food and Drug Administration (FDA) has approved Tecentriq (atezolizumab; Genentech), in combination with carboplatin and etoposide, for the first-line treatment of adult patients with extensive-stage small cell lung cancer.
New AI Model May Predict Cancerous Lung Nodules
The Lung Cancer Causal Model relies on CT features, demographics, clinical data, and improves on current methods.
United States Agencies Probing Johnson & Johnson Over Asbestos in Talc
Johnson & Johnson is being investigated over possible asbestos contamination of the company’s baby powder and other talc-based products.
Next post in Lung Cancer
